NCT01826981 - Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Participants With Chronic Genotype 1, 2, 3, or 6 HCV Infection | Biotech Hunter

Enrollment

359

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

March 31, 2015

Study Completion Date

May 31, 2015

Conditions

Chronic Hepatitis C

Interventions

DRUG

LDV/SOF

Ledipasvir/sofosbuvir (LDV/SOF) (90 /400 mg) fixed-dose combination (FDC) tablet administered orally once daily

DRUG

SOF

SOF 400 mg tablet administered orally once daily

DRUG

RBV

Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)

DRUG

Peg-IFN

pegylated interferon (Peg-IFN) 180 µg administered subcutaneously once weekly

DRUG

GS-9669

GS-9669 500 mg (2 × 250 mg tablet) administered orally once daily

DRUG

VEL

Velpatasvir (VEL) tablet(s) administered orally once daily

Trial Locations (2)

Unknown

Auckland Clinical Studies Ltd., Auckland

Christchurch Clinical Studies Trust, Christchurch